Hypervascular Tumors clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Showing trials for
Instylla HES Hypervascular Tumor Pivotal Study
Sorry, in progress, not accepting new patients
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.
Irvine, California and other locations
Our lead scientists for Hypervascular Tumors research studies include Nadine Abi-Jaoudeh, M.D..
Last updated: